Methyl selenocysteine: Single-dose pharmacokinetics in men

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1938-1944

  Marshall, James R ^a   Ip, Clement ^a   Romano, Karen ^a   Fetterly, Gerald ^a   Fakih, Marwan ^a   Jovanovic, Borko ^b   Perloff, Marjorie ^d   Crowell, James ^d   Davis, Warren ^a   French Christy, Renee ^a   Dew, Alexander ^b   Coomes, Margerie ^b   Bergan, Raymond ^b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; METHYLSELENOCYSTEINE; NITROGEN; PLACEBO; SELENOCYSTEINE; UNCLASSIFIED DRUG; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRY VISION; BRONCHOSPASM; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG URINE LEVEL; DYSGEUSIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NAIL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABRASION; SORE THROAT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY FREQUENCY;

ADULT; COHORT STUDIES; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MAXIMUM TOLERATED DOSE; ORGANOSELENIUM COMPOUNDS; SELENOCYSTEINE; TREATMENT OUTCOME;

EID: 81555202942     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0259     Document Type: Article

References (38)

1. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. J Am Diet Assoc 2000;100:537-640.
2. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24. (Pubitemid 28407088)
3. Brooks JD, Jeffrey ME, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8. (Pubitemid 33065210)
4. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between α-tocopherol, γ-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23. (Pubitemid 32045898)
5. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703. (Pubitemid 38660232)
6. Nomura AMY, Lee J, Stemmermann GN, Combs GF. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
7. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63. (Pubitemid 26427723)
8. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int 2003;91:608-12. (Pubitemid 36583728)
9. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9. (Pubitemid 34760821)
10. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF, et al. the Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81. (Pubitemid 37279333)
11. Karp DD, Lee SJ, Shaw Wright GL, Johnson DH, Johnston MR, et al. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 Suppl:8s. Abstr nr. CRA7004.
12. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009;301:E1-E13.
13. Uden PC, Boakye HT, Kahakachchi C, Hafezi R, Nolibos P, Block E, et al. Element selective characterization of stability and reactivity of selenium species in selenized yeast. J Anal At Spectrom 2004;19:65-73.
14. Poerschke RL, Franklin MR, Moos PJ. Modulation of redox status in human lung cell lines by organoselenocompounds: slenazolidines, selenomethionine, and methylseleninic acid. Toxicol In Vitro 2008;22:1761-7.
15. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005;64:527-42. (Pubitemid 41705454)
16. Das RK, Bhattacharya S. Anti-tumour promoting activity of diphenylmethyl selenocyanate against two-stage mouse skin carcinogenesis. Asian Pac J Cancer Prev 2005;6:181-8.
17. Gopalakrishna R, Gundimeda U. Antioxidant regulation of protein kinase C in cancer prevention. J Nutr 2002;132:3819s-23s. (Pubitemid 35435072)
18. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001;61:7071-8. (Pubitemid 32946498)
19. Zhao R, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methionase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther 2006;5:3275-84. (Pubitemid 46092071)
20. Xiang N, Zhao R, Zhong W. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemother Pharmacol 2009;63:351-62.
21. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54. (Pubitemid 28509845)
22. Patterson BH, Levander OA, Helzlsouer KJ, McAdam PA, Lewis SA, Taylor PR, et al. Human selenite metabolism: a kinetic model. Am J Physiol 1989;257:556-67.
23. Swanson CA, Patterson BH, Levander OA, Veillon C, Taylor PR, Helzlsouer KJ, et al. Human (74Se) selenomethionine metabolism: a kinetic model. Am J Clin Nutr 1991;54:917-26. (Pubitemid 21899016)
24. Ip C, Birringer M, Block E, Kotrebai M, Tyson JF, Uden PC, et al. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem 2000;48:2062-70. (Pubitemid 30431189)
25. Ip C, Thompson HJ, Zhu Z, et al. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6. (Pubitemid 30395810)
26. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52-9. (Pubitemid 36070419)
27. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 2006;15:804-10.
28. Ip C, Zhu Z, Thompson HJ, Lisk D, Ganther H. Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. Anticancer Res 1999;19:2875-80. (Pubitemid 30042565)
29. Ganther HE. Selenium metabolism and mechanisms of cancer prevention. In: AICR, editor. Nutrition and cancer prevention. New York: Kluwer Academic/Plenum; 2000. p. 119-30.
30. Ohta Y, Suzuki KT. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol 2008;226:169-77. (Pubitemid 350297344)
31. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
32. Papp LV, Lu J, Holmgren A, Khanna KK. Comprehensive invited review from selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 2007;9:775-806. (Pubitemid 46919583)
33. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, et al. Characterization of mammalian selenoproteomes. Science 2003;300:1439-43. (Pubitemid 36638165)
34. Lee BJ, Worland PJ, Davis JN, Stadtman TC, Hatfield DL. Identification of a selenocysteyl-tRNA(ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem 1989;264:9724-7. (Pubitemid 19159229)
35. Ip C, Marshall J, Park YM, Zhang H, Dong Y, Wu Y, et al. Selenium and Cancer Prevention. In: Nutritional Oncology 2nd ed. Heber D, Blackburn GL, Go VLW, Milner J (eds) San Diego: Academic Press, pp. 573-81.
36. Jackson MI, Combs GFJ. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 2008;11:718-26.
37. Johnson WD, Morrissey RL, Kapetanovic I, Crowell J, McCormick DL. Subchronic oral toxicity studies of Se-methylselenocysteine, and organoselenium compound for breast cancer prevention. Food Chem Toxicol. 2008 Mar; 46(3):1068-78 Epub 2007 Nov 12.
38. Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer 2001;40:12-7. (Pubitemid 34037509)